Updated Overall Survival (Os) Results From The Phase Iii Monaleesa-7 Trial Of Pre- Or Perimenopausal Patients With Hormone Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (Hr+/Her2-) Advanced Breast Cancer (Abc) Treated With Endocrine Therapy (Et) +/- Ribociclib